The Novavax share flared up on Friday after the final phase test showed that the coronavirus vaccine is 96.4% effective against the original virus strain that Covid-19 causes.
X
The two-shot regime prevented 100% of serious Covid cases, including hospitalization and death, in the UK study. Novavax (NVAX) also reported the results of middle school tests in South Africa. The vaccine was 55.4% effective against infection in HIV-negative participants. It is more difficult to target a strain in South Africa for vaccines.
Thursday has been a year since the World Health Organization officially declared the Covid 19 pandemic, and with this data in hand, we are even more motivated to promote our vaccine as a potential weapon in the fight against the Covid suffering. 19 caused, to terminate. “” Novavax CEO Stanley Erck said in a written statement.
On the stock market, the Novavax share rose 8.1% to 202.77 today.
Novavax stock rises in Phase 3 test
The UK study enrolled more than 15,000 participants aged 18-84 years. Of these, 27% were volunteers over the age of 65.
In addition to protecting 96.4% against the original strain, the vaccine also blocked 86.3% of Covid cases due to a mutated strain first identified in the UK. The British strain is considered more contagious, but has not yet escaped the vaccines widely.
Among people aged 65 and older, there were 10 cases of Covid-19 and 90% of them occurred in the placebo group.
The South African study included 2665 healthy adults. A smaller group of 240 included medically stable, HIV-positive adults. Overall, the drug was 48.6% effective against predominantly different strains, Novavax said. HIV-negative participants experienced 55.4% efficacy.
Shares continue their rampage
The Novavax stock has gone on a rampage as hopes for the coronavirus vaccine rise.
In terms of numbers, the efficiency of 96.4% is better than the results of Pfizer (PFE), Modern (MRNA) and Johnson & Johnson (JNJ). All three have approved vaccines in the United States. In the final phase testing, the vaccine was 95%, 94.1% and 66% effective against the virus, respectively. J & J’s vaccine is the only one-shot drug in the packaging.
A new analysis of Israel earlier this week suggested Pfizer’s BioNTech (BNTX) -partnered Covid vaccine may be 97% effective two weeks after the second dose.
It is important to note that experts generally do not recommend making comparisons between studies due to differences in patient populations and objectives. Up to that point, Novavax and J&J had been testing their vaccines at a time when variants were emerging. Pfizer and Moderna did not take note of the mutations in their press releases at the time.
The rise in Novavax stock this year is reflected in the best possible relative strength rating of 99. The RS rating shows the performance of a stock in the 12 months against all other stocks. According to IBD Digital, it is Novavax share in the best 1% of all shares.
Follow Allison Gatlin on Twitter @IBD_AGatlin.
YOU MAY ALSO LIKE THIS:
Biotech Stock Catapults After GSK Partners Covid Medicine Passes Key Test
There is evidence of drug supply indicating that the covide vaccine is almost 100% effective
Option trading: how to start using options, how to manage risks
Join IBD Live for shares every morning before the open
Best growth stocks to buy and look at: see IBD stock list updates